Daily Anesthesiology Research Analysis
Analyzed 120 papers and selected 3 impactful papers.
Summary
Three impactful anesthesiology-relevant studies stood out today: a methods paper proposes a patient-centered efficacy endpoint (ROOT) that aligns better with clinical meaning than SPID in acute pain trials; a large propensity-matched analysis links sugammadex use to fewer respiratory failures and ICU admissions after upper GI endoscopy; and a national registry study shows that combining preoperative hemoglobin optimization with intraoperative blood-conservation reduces transfusions in valve surgery.
Research Themes
- Patient-centered endpoints and trial methodology in acute pain
- Neuromuscular blockade reversal and postoperative pulmonary outcomes
- Integrated patient blood management in cardiac surgery
Selected Articles
1. Duration of clinically meaningful improvement in pain as a patient-centered endpoint in acute pain trials.
Using data from 34 phase 2/3 analgesic trials (N=11,028), the study proposes ROOT—the proportion of time with clinically important pain reduction without recent rescue—as a patient-centered endpoint. ROOT reached concordant conclusions with SPID in 92.2% of 204 comparisons while avoiding last-observation-carried-forward imputation after rescue, which distorted temporal treatment effects. ROOT preserves interpretability and statistical efficiency, offering a credible alternative to SPID.
Impact: This methodological advance could shift primary endpoints in acute pain trials toward more patient-centered, bias-resistant measures, influencing regulatory and trial design standards.
Clinical Implications: Sponsors and investigators can adopt ROOT to reduce reliance on imputation after rescue analgesia and to better reflect clinically meaningful benefit, potentially improving decision-making in analgesic development.
Key Findings
- ROOT is defined as the proportion of study time with ≥50% pain reduction without recent rescue or early discontinuation.
- Across 34 trials (N=11,028), ROOT and SPID produced concordant statistical conclusions in 92.2% of 204 comparisons.
- LOCF imputation after rescue distorted temporal treatment effects, especially during periods of high rescue use; ROOT avoided this bias.
Methodological Strengths
- Large multi-trial reanalysis using regulatory-grade datasets (phase 2/3).
- Direct head-to-head comparison of endpoints with pre-specified handling of rescue medication.
Limitations
- ROOT thresholds (eg, 50% reduction) may require disease- or context-specific validation.
- Heterogeneity across included trials could influence generalizability despite high concordance.
Future Directions: Prospective validation of ROOT as a primary endpoint in diverse acute pain indications; exploration of alternative responder thresholds and integration into adaptive and Bayesian trial designs.
Current US Food and Drug Administration (FDA) guidance recommends the sum of pain intensity differences (SPID) as the primary efficacy endpoint for acute pain trials, which lacks validated thresholds for clinically meaningful change and requires imputation of pain scores after rescue medication use. We introduce the responder outcome over time (ROOT), defined as the proportion of study time a participant experiences clinically important improvement in pain intensity without recent rescue medication use or early discontinuation. The ROOT combi
2. Sugammadex vs. neostigmine and the risk of postoperative pulmonary complications after upper gastrointestinal endoscopic procedures: a propensity score matched analysis of 15,730 patients.
In a federated, multicentre, propensity-matched cohort of 15,730 adults undergoing upper GI endoscopy under general anesthesia, sugammadex was associated with lower tracheal extubation failure (absolute risk reduction 1.91%; NNT 52), less atelectasis/collapse, and fewer unplanned ICU admissions versus neostigmine. Benefits persisted among patients without chronic pulmonary disease.
Impact: This large comparative-effectiveness analysis informs routine reversal strategy in endoscopy anesthesia, linking sugammadex to fewer serious respiratory complications.
Clinical Implications: Prefer sugammadex when feasible for reversing rocuronium during upper GI endoscopy under general anesthesia to reduce extubation failure and unplanned ICU admission risk.
Key Findings
- After matching (7,865 per group), extubation failure was 3.88% with sugammadex vs 5.79% with neostigmine (ARR 1.91%; NNT 52).
- Sugammadex reduced atelectasis/collapse (6.74% vs 7.76%) and unplanned ICU admission (8.27% vs 9.45%).
- Benefits were consistent in patients without chronic pulmonary disease.
Methodological Strengths
- Large multicentre federated dataset with robust propensity score matching.
- Clinically relevant, hard outcomes with predefined subgroup analyses.
Limitations
- Observational design susceptible to residual confounding and indication bias.
- Details on neuromuscular monitoring and depth of block at reversal not reported.
Future Directions: Prospective randomized trials incorporating quantitative neuromuscular monitoring to confirm respiratory outcome advantages and cost-effectiveness analyses in endoscopy populations.
INTRODUCTION: Postoperative pulmonary complications after upper gastrointestinal endoscopic procedures under general anaesthesia are clinically important and may be exacerbated by residual neuromuscular block. We evaluated whether antagonism of neuromuscular block with sugammadex rather than neostigmine is associated with improved respiratory outcomes in this setting. METHODS: We performed a retrospective multicentre cohort study using a federated health record network. Adults undergoing upper gastrointestinal endoscopy who received rocuronium and antagonism of neuromuscular blockade with either sugammadex or neostigmine were identified. Propensity score matched analysis was conducted. The primary outcome was failure of tracheal extubation, defined as postoperative ventilator dependence or tracheal reintubation within 30 days. Secondary outcomes included coded lung atelectasis and unplanned admission to an ICU. A prespecified subgroup analysis was performed in patients without chronic pulmonary disease. RESULTS: After matching, 15,730 patients were included (7865 per group). Failure of tracheal extubation occurred in 305 patients (3.88%) in the sugammadex group and 455 patients (5.79%) in the neostigmine group (risk ratio 1.49, 95%CI 1.30-1.72, p < 0.0001), an absolute risk reduction of 1.91% and a number needed to treat of 52. Sugammadex was also associated with lower rates of lung atelectasis or collapse (6.74% compared with 7.76%, p = 0.014) and unplanned ICU admission (8.27% compared with 9.45%, p = 0.009). In the subgroup without chronic pulmonary disease (4624 patient pairs), failure of tracheal extubation occurred in 3.05% and 4.97% and unplanned ICU admission in 6.66% and 8.54% after sugammadex and neostigmine, respectively (all p < 0.001). DISCUSSION: In this large cohort of adults undergoing upper gastrointestinal endoscopy, sugammadex use was associated with important reductions in tracheal extubation failure, lung atelectasis or collapse, and unplanned ICU admission compared with neostigmine, including in those patients without known chronic pulmonary disease. WHAT WE DID: We studied a large group of adults who had a camera test of their stomach or food pipe while under general anaesthesia. During these procedures, doctors used medicines to relax the muscles and then gave another medicine to reverse this effect at the end. We compared two reversal medicines, called sugammadex and neostigmine, to see which one led to better breathing outcomes after the procedure. WHY DID WE DO IT: After anaesthesia, some patients can have breathing problems if the muscle‐relaxing medicine has not fully worn off. This can lead to serious complications, like needing help to breathe again or being admitted to intensive care. We wanted to find out which reversal medicine is safer and helps patients recover their breathing more effectively. WHAT WE FOUND: We found that patients who received sugammadex were less likely to have breathing problems after their procedure compared with those who received neostigmine. They were less likely to need a breathing tube again, less likely to have parts of their lungs collapse and less likely to need unexpected care in intensive care. This was true even for patients who did not already have lung disease. Overall, sugammadex appeared to be the safer option for helping patients breathe normally again after anaesthesia.
3. Patient blood management in cardiac valve surgery: combined effects of preoperative hemoglobin optimization and intraoperative blood conservation.
In a national multicenter registry of 9,889 elective valve surgeries, preoperative anemia (Hb <13 g/dL) markedly increased transfusion risk. The combined use of tranexamic acid and intraoperative cell salvage reduced transfusion compared with no conservation, while either alone had limited effect. Non-anemic patients receiving both strategies had the lowest transfusion rates.
Impact: Demonstrates real-world synergy between preoperative anemia correction and intraoperative conservation, operationalizing integrated patient blood management in valve surgery.
Clinical Implications: Adopt a dual PBM strategy: target preoperative Hb ≥13 g/dL and combine tranexamic acid with intraoperative cell salvage to minimize transfusion during valve surgery.
Key Findings
- Overall transfusion rate was 53% among 9,889 valve surgeries; anemia (Hb <13 g/dL) increased transfusion risk (70.2% vs 42.7%).
- Combined tranexamic acid and cell salvage reduced transfusion compared with no conservation (47.7% vs 52.3%; adjusted OR 0.83).
- Non-anemic patients receiving both strategies had the lowest transfusion (37.6%), whereas anemic patients without conservation had the highest (74.9%; adjusted OR 4.95).
Methodological Strengths
- Large nationwide multicenter cohort leveraging a dedicated PBM registry.
- Joint modeling of preoperative and intraoperative strategies to assess combined effects.
Limitations
- Retrospective observational design with potential residual confounding.
- Incomplete intraoperative data for a subset may introduce selection bias in secondary analyses.
Future Directions: Prospective PBM pathways testing anemia correction protocols (e.g., IV iron/ESAs) plus standardized intraoperative conservation bundles with patient-centered outcomes and cost-effectiveness.
BACKGROUND: Transfusion practices in cardiac valve surgery remain variable despite evidence supporting integrated patient blood management strategies. This study evaluated the independent and combined effects of preoperative hemoglobin status and intraoperative blood conservation techniques on transfusion requirements in elective open cardiac valve surgery. METHODS: We conducted a nationwide retrospective multicenter cohort study using data from the national Maturity Assessment Model for Patient Blood Management registry. Adult patients undergoing elective open cardiac valve surgery between 2016 and 2022 in 23 Spanish hospitals were included. Anemia was defined as preoperative hemoglobin <13 g/dL, irrespective of sex. The primary outcome was red blood cell transfusion during the index hospital admission. RESULTS: A total of 9889 patients were analyzed, with an overall transfusion rate of 53%. Anemic patients (37.3%) had higher transfusion rates than non-anemic patients (70.2% vs. 42.7%). In a separate model restricted to 5763 patients with intraoperative data, combined use of tranexamic acid and intraoperative cell salvage was associated with lower transfusion risk compared with no blood conservation strategy (47.7% vs. 52.3%; adjusted odds ratio 0.83; 95% confidence interval 0.71-0.97), whereas use of either strategy alone showed no meaningful transfusion reduction. When preoperative hemoglobin status and intraoperative strategies were analyzed jointly, the lowest transfusion rate (37.6%) occurred in non-anemic patients receiving both strategies, whereas anemic patients without blood conservation had the highest rate (74.9%; adjusted odds ratio 4.95; 95% confidence interval 4.10-5.97). CONCLUSIONS: Combined implementation of adequate preoperative hemoglobin levels and intraoperative blood conservation strategies was associated with lower transfusion rates in elective cardiac valve surgery, supporting the value of integrated perioperative patient blood management pathways in real-world practice.